InvestorsHub Logo
Followers 14
Posts 698
Boards Moderated 0
Alias Born 04/06/2011

Re: EagleD post# 8840

Friday, 05/01/2020 6:02:15 PM

Friday, May 01, 2020 6:02:15 PM

Post# of 16703
There it is! Four phsae2 trials and Cash to make them go...

The Korean Phase 2 trials appear to me to be more directed toward COVID-19 thru MOHW, South Korea. Ifenprodil is an approved drug in South Korea for other indications and is being tested for Repurposing, IMO. They have a specific Korean Lead investigator/sponsor/University led with Dr. Dong.
" The Phase 2 human trials will consist of 40 patients during a 4-week trial and will be testing the efficacy of Ifenprodil in infected patients with Covid-19. Dr. Dong Sik Jung, Professor in the Division of Infectious Disease of Dong-A University Hospital in Busan, South Korea will be the lead principal investigator overseeing the trials and patient enrollment for Phase 2 clinical trials is set to take place on May 8th, 2020. The CEO of AGN Christopher Moreau stated, “This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program”.
Watch 4/23 Video, mins 4:00 to 5:30 for Recruitment, Dr Moroue explains that the patients are ready and about Dr Dong... heck watch it all again...

Looks to me like the current USFDA authorized trials are set more specifically for "Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough", NCT04318704. The Exclusion Criteria section has lots of limits and the Inclusion Criteria section does not mention COVID and appears to me to be IPF specific.

Novotech efforts for Ifenprodil in Austrailia also seem to be directed at IPF and ALI, IMO.

Now Canada Trial approvals seem eminent,, with their Phase 2b/3 plans. Canada seems to present the best of all possibilities for Algernon Investors.

That's FOUR Trials !! The South Korean effort starts May 8...
As you say They Have Money in the Bank...

Call me a sore thumb.



Maybe check out Giliad/Remisifir(?) relationship with Wuhan, VI.